Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Sep 4;83(7):853–857. doi: 10.1054/bjoc.2000.1401

A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma

M E R O’Brien 1,2, A Saini 1, I E Smith 1, A Webb 1, K Gregory 1, R Mendes 1,3, C Ryan 2, K Priest 1, K V Bromelow 3, R D Palmer 4, N Tuckwell 6, D A Kennard 5, B E Souberbielle 1,3
PMCID: PMC2374669  PMID: 10970684

Abstract

Mycobacterial preparations have been used with limited success against cancer apart from superficial bladder cancer. Recently, a therapeutic vaccine derived from Mycobacterium vaccae has been given to patients with prostate cancer and melanoma indicating a possible beneficial effect on disease activity in such patients. We have recently initiated a series of randomized studies to test the feasibility and toxicity of combining a preparation of heat-killed Mycobacterium vaccae (designated SRL172) with a multidrug chemotherapy regimen to treat patients with inoperable non-small cell lung cancer (NSCLC) and mesothelioma. 28 evaluable patients with previously untreated symptomatic NSCLC and mesothelioma were randomized to receive either 3 weekly intravenous combination chemotherapy alone, or chemotherapy given with monthly intra-dermal injections of SRL172. Safety and tolerability were scored by common toxicity criteria and efficacy was evaluated by survival of patients and by tumour response assessed by CT scanning. The toxicity of chemotherapy was similar in the two groups. SRL172 caused mild inflammation at the injection site. In the group of patients randomized to receive chemotherapy combined with SRL172, there was a trend towards improved response rate (54% vs. 33%) with more patients in the combined arm receiving radical surgery and radiotherapy, improved median survival (9.7 months vs. 7.5 months) and improved 1 year survival (42% vs. 18%). SRL172 appeared to improve sleep (P = 0.08) and improved appetite (P = 0.01). There was no detectable change in serum cytokine levels for gamma-interferon and TNF-α before and after treatment. In patients with NSCLC and mesothelioma, there may be a beneficial interaction when chemotherapy is administered in combination with SRL172. Confirmation of this effect and further investigation is underway in a randomized phase III trial and in laboratory models. © 2000 Cancer Research Campaign

Keywords: lung cancer, mesothelioma, SRL172, mycobacterium vaccae, chemotherapy

Full Text

The Full Text of this article is available as a PDF (54.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Al-Moundhri M., O'Brien M., Souberbielle B. E. Immunotherapy in lung cancer. Br J Cancer. 1998 Aug;78(3):282–288. doi: 10.1038/bjc.1998.486. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ellis P. A., Smith I. E., Hardy J. R., Nicolson M. C., Talbot D. C., Ashley S. E., Priest K. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer. 1995 Feb;71(2):366–370. doi: 10.1038/bjc.1995.74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ellis P. A., Smith I. E., McCarthy K., Detre S., Salter J., Dowsett M. Preoperative chemotherapy induces apoptosis in early breast cancer. Lancet. 1997 Mar 22;349(9055):849–849. doi: 10.1016/s0140-6736(05)61752-7. [DOI] [PubMed] [Google Scholar]
  4. Ferrarini M., Heltai S., Zocchi M. R., Rugarli C. Unusual expression and localization of heat-shock proteins in human tumor cells. Int J Cancer. 1992 Jun 19;51(4):613–619. doi: 10.1002/ijc.2910510418. [DOI] [PubMed] [Google Scholar]
  5. Grange J. M., Stanford J. L., Rook G. A. Tuberculosis and cancer: parallels in host responses and therapeutic approaches? Lancet. 1995 May 27;345(8961):1350–1352. doi: 10.1016/s0140-6736(95)92542-2. [DOI] [PubMed] [Google Scholar]
  6. Hanna M. G., Jr, Key M. E. Immunotherapy of metastases enhances subsequent chemotherapy. Science. 1982 Jul 23;217(4557):367–369. doi: 10.1126/science.6283635. [DOI] [PubMed] [Google Scholar]
  7. Hrouda D., Baban B., Dunsmuir W. D., Kirby R. S., Dalgleish A. G. Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172). Br J Urol. 1998 Oct;82(4):568–573. doi: 10.1046/j.1464-410x.1998.00803.x. [DOI] [PubMed] [Google Scholar]
  8. Maraveyas A., Baban B., Kennard D., Rook G. A., Westby M., Grange J. M., Lydyard P., Stanford J. L., Jones M., Selby P. Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes. Ann Oncol. 1999 Jul;10(7):817–824. doi: 10.1023/a:1008307821189. [DOI] [PubMed] [Google Scholar]
  9. Mitchell M. S. Chemotherapy in combination with biomodulation: a 5-year experience with cyclophosphamide and interleukin-2. Semin Oncol. 1992 Apr;19(2 Suppl 4):80–87. [PubMed] [Google Scholar]
  10. Pellegrini P., Berghella A. M., Del Beato T., Cicia S., Adorno D., Casciani C. U. Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother. 1996 Jan;42(1):1–8. doi: 10.1007/s002620050244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Webb A., O'Brien M. E. Where to go with new expensive treatments in NSCLC. Br J Cancer. 1998 Jul;78(2):159–162. doi: 10.1038/bjc.1998.458. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES